Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCX915
- Development stage
- Discontinued
- Lead developer
- ChemoCentryx
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CCX915 is a small molecule drug developed by ChemoCentryx as an orally available antagonist of the C-C chemokine receptor type 2 (CCR2). Its mechanism of action involves selectively inhibiting CCR2-mediated migration of inflammatory white blood cells, which is implicated in the pathogenesis of inflammatory diseases such as multiple sclerosis and other neurologic disorders. By targeting CCR2 with high specificity, CCX915 was designed to avoid some undesirable side effects associated with traditional immunosuppressive therapies. The drug reached phase 1 clinical trials for multiple sclerosis but development was discontinued[1][3][4].
02
Targets
CCR2 (Chemokine (C-C motif) Receptor 2)
Beyond the preview
Go deeper on CCX915.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCX915.